Fosamax Exposure Linked to Osteonecrosis of the Jaw: Mechanisms and Evidence
Latest update (2026-05)
FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]
From General Health Awareness to Specific Risk Assessment
The legacy of general health and science information has long emphasized the importance of evidence-based awareness in preventive medicine. Within this framework, public health communications have historically focused on broad risk factors and lifestyle modifications to mitigate adverse outcomes. This foundational approach has successfully guided patients and providers toward informed decision-making regarding therapeutic interventions. Transitioning from this general health context, a more targeted concern emerges when considering specific pharmaceutical exposures in clinical practice. The shift from population-level health guidance to occupational and patient-specific risk assessment requires careful attention to medication-related adverse events. In particular, the association between bisphosphonate therapy, such as Fosamax exposure, and the development of osteonecrosis of the jaw represents a critical area where general health principles must be adapted to address specialized exposure scenarios. This pivot from broad health education to focused exposure analysis underscores the need for nuanced risk communication. While general health information provides a solid foundation, the transition to occupational and therapeutic exposure contexts demands precise evaluation of individual risk factors. The legacy of comprehensive health science thus serves as a springboard for deeper investigation into specific drug-tissue interactions, without prematurely venturing into mechanistic claims. This balanced approach ensures that risk awareness remains grounded in established health communication practices while addressing emerging clinical concerns.
Fosamax and Osteonecrosis of the Jaw: A Documented Adverse Effect
Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its use has been associated with a serious adverse effect: osteonecrosis of the jaw (ONJ). This condition involves bone death in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). ONJ has been reported in patients taking bisphosphonates, including Fosamax and Fosamax Plus D (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The clinical presentation of ONJ typically involves exposed necrotic bone in the maxillofacial region, often following dental procedures. Diagnosis relies on clinical examination and imaging, with a focus on identifying bone exposure that persists for more than eight weeks in the absence of prior radiation therapy. Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).
Mechanistic Pathways and Evidence of Causation
Mechanistic pathways linking Fosamax to ONJ involve the drug's pharmacology as a bisphosphonate. Fosamax inhibits osteoclast-mediated bone resorption, which reduces bone turnover. In the jawbone, this suppression of remodeling may impair the ability to repair microdamage and maintain tissue health. Multiscale characterization of jawbone in animal models treated with bisphosphonates, including alendronate (the active ingredient in Fosamax), has provided information on jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). Studies in estrogen-deficient rats have examined the effects of bisphosphonate treatment on jawbone properties, including tissue mineral density distribution and mechanical stability of teeth in the alveolar socket (https://pubmed.ncbi.nlm.nih.gov/40345077/). These findings suggest that bisphosphonate-induced alterations in bone matrix properties may contribute to ONJ pathogenesis. The timeline between Fosamax exposure and documented harm varies. The time to onset of symptoms after starting the drug can range from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset experienced recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Regarding adequacy of warnings, the prescribing information for Fosamax includes a section on osteonecrosis of the jaw under "Warnings and Precautions" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This section notes that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and lists known risk factors. However, the warning does not quantify the absolute risk or provide specific guidance on monitoring for ONJ in all patients. The label also states that the optimal duration of use has not been determined and suggests considering drug discontinuation after 3 to 5 years for low-risk patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This may be relevant to ONJ risk, as longer exposure is associated with increased risk. Causation-related considerations for affected patients include the need to establish a temporal relationship between Fosamax use and ONJ onset, rule out other causes (e.g., cancer, radiation therapy), and consider the presence of known risk factors. The recurrence of symptoms upon rechallenge with bisphosphonates supports a causal link (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Patients who develop ONJ while on Fosamax should discontinue the drug if severe symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label advises that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the decision to discontinue should be made on a case-by-case basis, weighing the benefits of osteoporosis treatment against the risk of ONJ. In summary, the evidence supports a causal association between Fosamax exposure and osteonecrosis of the jaw, with plausible mechanisms involving suppressed bone turnover in the jawbone. The timeline of onset can be variable, and risk is increased with longer exposure and presence of dental risk factors. Warnings in the prescribing information address ONJ but may not fully convey the risk to all patients. Affected individuals should consider discontinuation of Fosamax and management of dental risk factors.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is osteonecrosis of the jaw (ONJ) and how is it linked to Fosamax?
Osteonecrosis of the jaw (ONJ) is a condition involving bone death in the jaw, often presenting as exposed necrotic bone in the maxillofacial region. Fosamax (alendronate), a bisphosphonate used for osteoporosis, has been associated with ONJ. The drug suppresses bone turnover, impairing repair of microdamage in the jawbone. ONJ has been reported in patients taking Fosamax, with risk factors including invasive dental procedures, longer exposure, and poor oral hygiene (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).
What are the mechanisms by which Fosamax may cause ONJ?
Fosamax inhibits osteoclast-mediated bone resorption, reducing bone turnover. In the jawbone, this suppression of remodeling may impair the ability to repair microdamage and maintain tissue health. Animal studies have shown bisphosphonate-induced alterations in jawbone matrix properties, including changes in tissue mineral density distribution and mechanical stability of teeth (https://pubmed.ncbi.nlm.nih.gov/40345077/). These changes contribute to ONJ pathogenesis.
How long does it take for ONJ to develop after starting Fosamax?
What should I do if I develop ONJ while taking Fosamax?
If you develop ONJ, consult your healthcare provider. Discontinuation of Fosamax may be recommended, especially if severe symptoms occur. The decision should be made on a case-by-case basis, weighing the benefits of osteoporosis treatment against the risk of ONJ. Management of dental risk factors, such as avoiding invasive procedures, is also advised (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Free Case & Eligibility Review
Individuals with documented Fosamax exposure and a related diagnosis may request an independent, no-cost eligibility review.